Skip to main content

10.05.2024 | Original Article

Detection and identification of circulating tumor cells in parathyroid tumors and correlation analysis with clinicopathological features

verfasst von: Jiacheng Wang, Xingran Jiang, Qian Wang, Teng Zhao, Hong Shen, Xing Liu, Dalin Feng, Rongfang Shen, Yuting Wang, Wenjing Yang, Bojun Wei

Erschienen in: Endocrine

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The differential diagnosis of parathyroid carcinoma (PC)/parathyroid adenoma (PA) in parathyroid tumors is critical for their management and prognosis. Circulating tumor cells (CTCs) identification in the peripheral blood of parathyroid tumors remains unknown. In this study, we proposed to investigate the differences of CTCs in PC/PA and the relationship with clinicopathologic features to assess its relevance to PC and value in identifying PC/PA.

Methods and materials

Peripheral blood was collected from 27 patients with PC and 37 patients with PA treated in our hospital, and the number of chromosome 8 aberrant CTCs was detected by negative magnetic bead sorting fluorescence in situ hybridization (NE-FISH). The differences of CTCs in PC/PA peripheral blood were compared and their diagnostic efficacy was evaluated, and the correlation between CTCs and clinicopathological features of PC was further explored.

Results

CTCs differed significantly in PC/PA (p = 0.0008) and were up-regulated in PC, with good diagnostic efficacy. CTCs combined with alkaline phosphatase (ALP) assay improved the diagnostic efficacy in identifying PC/PA (AUC = 0.7838, p = 0.0001). The number of CTCs was correlated with tumor dimensions, but not significantly correlated with clinical markers such as calcium and PTH and pathological features such as vascular invasion, lymph node metastasis and distant metastasis.

Conclusion

As a non-invasive liquid biopsy method, CTCs test combined with ALP test can be used as an important reference basis for timely and accurate identification and treatment of PC. It is of great significance to improve the current situation of PC diagnosis, treatment and prognosis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat F. Cetani, E. Pardi, C. Marcocci, Update on parathyroid carcinoma. J. Endocrinol. Invest. 39(6), 595–606 (2016)CrossRefPubMed F. Cetani, E. Pardi, C. Marcocci, Update on parathyroid carcinoma. J. Endocrinol. Invest. 39(6), 595–606 (2016)CrossRefPubMed
2.
Zurück zum Zitat S. Xue, H. Chen, C. Lv et al. Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. Clin. Endocrinol. 85(1), 29–36 (2016)CrossRef S. Xue, H. Chen, C. Lv et al. Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. Clin. Endocrinol. 85(1), 29–36 (2016)CrossRef
3.
Zurück zum Zitat P. Wang, S. Xue, S. Wang et al. Clinical characteristics and treatment outcomes of parathyroid carcinoma: a retrospective review of 234 cases. Oncol. Lett. 14(6), 7276–7282 (2017)PubMedPubMedCentral P. Wang, S. Xue, S. Wang et al. Clinical characteristics and treatment outcomes of parathyroid carcinoma: a retrospective review of 234 cases. Oncol. Lett. 14(6), 7276–7282 (2017)PubMedPubMedCentral
4.
Zurück zum Zitat B. Wei, T. Zhao, H. Shen et al. Extended En bloc reoperation for recurrent or persistent parathyroid carcinoma: analysis of 31 cases in a single institute experience. Ann. Surg. Oncol. 29(2), 1208–1215 (2022)CrossRefPubMed B. Wei, T. Zhao, H. Shen et al. Extended En bloc reoperation for recurrent or persistent parathyroid carcinoma: analysis of 31 cases in a single institute experience. Ann. Surg. Oncol. 29(2), 1208–1215 (2022)CrossRefPubMed
5.
Zurück zum Zitat E.M. Ryhänen, H. Leijon, S. Metso et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 56(7), 991–1003 (2017)CrossRefPubMed E.M. Ryhänen, H. Leijon, S. Metso et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 56(7), 991–1003 (2017)CrossRefPubMed
6.
Zurück zum Zitat J.C.M. Wan, C. Massie, J. Garcia-Corbacho et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17(4), 223–238 (2017)CrossRefPubMed J.C.M. Wan, C. Massie, J. Garcia-Corbacho et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17(4), 223–238 (2017)CrossRefPubMed
7.
Zurück zum Zitat J. Kaiser, ‘Liquid biopsy’ for cancer promises early detection. Science. 359(6373), 259 (2018)CrossRefPubMed J. Kaiser, ‘Liquid biopsy’ for cancer promises early detection. Science. 359(6373), 259 (2018)CrossRefPubMed
8.
Zurück zum Zitat A. Bardelli, K. Pantel, Liquid biopsies, what we do not know (Yet). Cancer Cell 31(2), 172–179 (2017)CrossRefPubMed A. Bardelli, K. Pantel, Liquid biopsies, what we do not know (Yet). Cancer Cell 31(2), 172–179 (2017)CrossRefPubMed
9.
Zurück zum Zitat Y. Sun, T.A. Haglund, A.J. Rogers et al. Review: microfluidics technologies for blood-based cancer liquid biopsies. Anal. Chim. Acta 1012, 10–29 (2018)CrossRefPubMed Y. Sun, T.A. Haglund, A.J. Rogers et al. Review: microfluidics technologies for blood-based cancer liquid biopsies. Anal. Chim. Acta 1012, 10–29 (2018)CrossRefPubMed
10.
Zurück zum Zitat X. Qiu, H. Zhang, Y. Zhao et al. Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer. J Cancer Res. Clin. Oncol. 148(3), 685–695 (2022)CrossRefPubMed X. Qiu, H. Zhang, Y. Zhao et al. Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer. J Cancer Res. Clin. Oncol. 148(3), 685–695 (2022)CrossRefPubMed
11.
Zurück zum Zitat M. Fontanilles, A. Duran-Pena, A. Idbaih, Liquid biopsy in primary brain tumors: looking for stardust! Curr. Neurol. Neurosci. Rep. 18(3), 13 (2018)CrossRefPubMed M. Fontanilles, A. Duran-Pena, A. Idbaih, Liquid biopsy in primary brain tumors: looking for stardust! Curr. Neurol. Neurosci. Rep. 18(3), 13 (2018)CrossRefPubMed
12.
Zurück zum Zitat J.F. Swennenhuis, G. van Dalum, L.L. Zeune et al. Improving the CellSearch(R) system. Expert Rev. Mol. Diagn. 16(12), 1291–1305 (2016)CrossRefPubMed J.F. Swennenhuis, G. van Dalum, L.L. Zeune et al. Improving the CellSearch(R) system. Expert Rev. Mol. Diagn. 16(12), 1291–1305 (2016)CrossRefPubMed
13.
Zurück zum Zitat T. Szabo Yamashita, A.S. Shirali, S. Meas et al. Is there a role for liquid biopsy in the surveillance of parathyroid carcinoma? Surgery. 175(1), 193–198 (2024)CrossRefPubMed T. Szabo Yamashita, A.S. Shirali, S. Meas et al. Is there a role for liquid biopsy in the surveillance of parathyroid carcinoma? Surgery. 175(1), 193–198 (2024)CrossRefPubMed
14.
Zurück zum Zitat R. Zhu, Z. Wang, Y. Hu, Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta-analysis based on individual patient data. Clin. Endocrinol. 92(4), 295–302 (2020)CrossRef R. Zhu, Z. Wang, Y. Hu, Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: A systematic review and meta-analysis based on individual patient data. Clin. Endocrinol. 92(4), 295–302 (2020)CrossRef
15.
Zurück zum Zitat Y. Li, J. Zhang, R.A. Poorni et al. Genotype of CDC73 germline mutation determines risk of parathyroid cancer. Endocr. Relat. Cancer 27(9), 483–494 (2020)CrossRefPubMedPubMedCentral Y. Li, J. Zhang, R.A. Poorni et al. Genotype of CDC73 germline mutation determines risk of parathyroid cancer. Endocr. Relat. Cancer 27(9), 483–494 (2020)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Y. Li, X. Zhang, J. Gong et al. Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. Chin. J. Cancer Res. 28(6), 579–588 (2016)CrossRefPubMedPubMedCentral Y. Li, X. Zhang, J. Gong et al. Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. Chin. J. Cancer Res. 28(6), 579–588 (2016)CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat R.L. Katz, T.M. Zaidi, D. Pujara et al. Identification of circulating tumor cells using 4-color fluorescence in situ hybridization: Validation of a noninvasive aid for ruling out lung cancer in patients with low-dose computed tomography-detected lung nodules. Cancer Cytopathol. 128(8), 553–562 (2020)CrossRefPubMed R.L. Katz, T.M. Zaidi, D. Pujara et al. Identification of circulating tumor cells using 4-color fluorescence in situ hybridization: Validation of a noninvasive aid for ruling out lung cancer in patients with low-dose computed tomography-detected lung nodules. Cancer Cytopathol. 128(8), 553–562 (2020)CrossRefPubMed
18.
Zurück zum Zitat Y. Chen, Z. Yang, Y. Wang et al. Karyotyping of circulating tumor cells for predicting chemotherapeutic sensitivity and efficacy in patients with esophageal cancer. BMC Cancer 19(1), 651 (2020)CrossRef Y. Chen, Z. Yang, Y. Wang et al. Karyotyping of circulating tumor cells for predicting chemotherapeutic sensitivity and efficacy in patients with esophageal cancer. BMC Cancer 19(1), 651 (2020)CrossRef
19.
Zurück zum Zitat J. Liu, C. Ma, X. Li et al. Circulating tumor cells correlating with Ki-67 predicts the prognosis of bladder cancer patients. Int. Urol. Nephrol. 55(2), 309–318 (2023)CrossRefPubMed J. Liu, C. Ma, X. Li et al. Circulating tumor cells correlating with Ki-67 predicts the prognosis of bladder cancer patients. Int. Urol. Nephrol. 55(2), 309–318 (2023)CrossRefPubMed
20.
Zurück zum Zitat Y. Xu, T. Qin, J. Li et al. Detection of circulating tumor cells using negative enrichment immunofluorescence and an in situ hybridization system in pancreatic cancer. Int. J. Molecual Sci. 18(4), 622 (2017)CrossRef Y. Xu, T. Qin, J. Li et al. Detection of circulating tumor cells using negative enrichment immunofluorescence and an in situ hybridization system in pancreatic cancer. Int. J. Molecual Sci. 18(4), 622 (2017)CrossRef
21.
Zurück zum Zitat L. Wang, Y. Li, J. Xu et al. Quantified postsurgical small cell size CTCs and EpCAM(+) circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse. Cancer Lett. 412, 99–107 (2018)CrossRefPubMed L. Wang, Y. Li, J. Xu et al. Quantified postsurgical small cell size CTCs and EpCAM(+) circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse. Cancer Lett. 412, 99–107 (2018)CrossRefPubMed
22.
Zurück zum Zitat M. Ye, X. Zheng, X. Ye et al. Circulating genetically abnormal cells add non-invasive diagnosis value to discriminate lung cancer in patients with pulmonary nodules ≤10 mm. Front. Oncol. 11, 638223 (2021)CrossRefPubMedPubMedCentral M. Ye, X. Zheng, X. Ye et al. Circulating genetically abnormal cells add non-invasive diagnosis value to discriminate lung cancer in patients with pulmonary nodules ≤10 mm. Front. Oncol. 11, 638223 (2021)CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat W. Wu, Z. Zhang, X.H. Gao et al. Clinical significance of detecting circulating tumor cells in colorectal cancer using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH). Oncotarget. 8(13), 21639–21649 (2017)CrossRefPubMedPubMedCentral W. Wu, Z. Zhang, X.H. Gao et al. Clinical significance of detecting circulating tumor cells in colorectal cancer using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH). Oncotarget. 8(13), 21639–21649 (2017)CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Q. Fan, S. Wei, L. Yang et al. The emerging role of exosome-derived non-coding RNAs in cancer biology. Cancer Lett. 414, 107–115 (2018)CrossRefPubMed Q. Fan, S. Wei, L. Yang et al. The emerging role of exosome-derived non-coding RNAs in cancer biology. Cancer Lett. 414, 107–115 (2018)CrossRefPubMed
26.
Zurück zum Zitat M.P. Davies, T.W. John Evans, F. Tahir et al. Parathyroid cancer: a systematic review of diagnostic biomarkers. Surgeon 19(6), e536–e548 (2021)CrossRefPubMed M.P. Davies, T.W. John Evans, F. Tahir et al. Parathyroid cancer: a systematic review of diagnostic biomarkers. Surgeon 19(6), e536–e548 (2021)CrossRefPubMed
27.
Zurück zum Zitat J. Wang, Q. Wang, T. Zhao et al. Expression profile of serum-related exosomal miRNAs from parathyroid tumor. Endocrine. 72(1), 239–248 (2021)CrossRefPubMed J. Wang, Q. Wang, T. Zhao et al. Expression profile of serum-related exosomal miRNAs from parathyroid tumor. Endocrine. 72(1), 239–248 (2021)CrossRefPubMed
28.
Zurück zum Zitat J. Krupinova, N. Mokrysheva, V. Petrov et al. Serum circulating miRNA-342-3p as a potential diagnostic biomarker in parathyroid carcinomas: a pilot study. Endocrinol. Diabetes Metab. 4(4), e00284 (2021)CrossRefPubMedPubMedCentral J. Krupinova, N. Mokrysheva, V. Petrov et al. Serum circulating miRNA-342-3p as a potential diagnostic biomarker in parathyroid carcinomas: a pilot study. Endocrinol. Diabetes Metab. 4(4), e00284 (2021)CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat W.-R. Liu, B. Zhang, C. Chen et al. Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer. Thorac. Cancer 11(11), 3234–3242 (2020)CrossRefPubMedPubMedCentral W.-R. Liu, B. Zhang, C. Chen et al. Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer. Thorac. Cancer 11(11), 3234–3242 (2020)CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat M. Feng, X. Ye, B. Chen et al. Detection of circulating genetically abnormal cells using 4-color fluorescence in situ hybridization for the early detection of lung cancer. J. Cancer Res. Clin. Oncol. 147(8), 2397–2405 (2021)CrossRefPubMedPubMedCentral M. Feng, X. Ye, B. Chen et al. Detection of circulating genetically abnormal cells using 4-color fluorescence in situ hybridization for the early detection of lung cancer. J. Cancer Res. Clin. Oncol. 147(8), 2397–2405 (2021)CrossRefPubMedPubMedCentral
Metadaten
Titel
Detection and identification of circulating tumor cells in parathyroid tumors and correlation analysis with clinicopathological features
verfasst von
Jiacheng Wang
Xingran Jiang
Qian Wang
Teng Zhao
Hong Shen
Xing Liu
Dalin Feng
Rongfang Shen
Yuting Wang
Wenjing Yang
Bojun Wei
Publikationsdatum
10.05.2024
Verlag
Springer US
Erschienen in
Endocrine
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03831-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.